KPTI Company Profile and Key Details

Q: Who are the executives of KPTI?

Mr. Michael J. Mano J.D.Senior Vice President, Gen. Counsel & Sec.Sarah ConnorsVice President of Corporation CommunicationsMr. Ran Frenkel R.Ph., RPhGlobal Head of Clinical OperationsMr. Pierre S. Sayad M.S., Ph.D.Vice President of Global Medical & Scientific AffairsMr. Richard A. Paulson M.B.A.Pres, Chief Executive Officer & DirectorDr. Sharon Shacham M.B.A., Ph.D.Co-Founder & Chairman of Scientific Advisory BoardMr. Michael P. Mason CPA, M.B.A.Executive Vice President, Chief Financial Officer & TreasurerMs. Sohanya Cheng M.B.A.Executive Vice President & Chief Commercial OfficerMr. Stuart PoultonExecutive Vice President & Chief Devel. OfficerDr. Mansoor Raza Mirza M.D.Clinical Consultant, Member of Scientific Advisory Board & Independent DirectorMr. Cameron PetersVice President of Fin., Assistant Treasurer & Principal Accounting OfficerMs. Elhan Webb C.F.A.Senior Vice President of Investor RelationsMr. James Accumanno J.D.Chief Compliance Officer

NASDAQ : KPTI

Karyopharm Therapeutics

$8.94

1.57+21.30%

At Close 4:00 PM

59.36

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Karyopharm Therapeutics Inc. (KPTI) stock surged +21.30%, trading at $8.94 on NASDAQ, up from the previous close of $7.37. The stock opened at $6.72, fluctuating between $6.72 and $9.94 in the recent session.

Stock Snapshot

7.37

Prev. Close

76.32M

Market Cap

6.72

Day Low

-0.61

P/E Ratio

-14.7

EPS (TTM)

-0.81

Cash Flow per Share

6.72

Open

8.54M

Number of Shares

9.9399

Day High

91.49%

Free Float in %

-1.19

Book Value

2.75M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 12, 2026	6.72	9.94	6.72	8.94	2.75M
Feb 11, 2026	6.58	7.38	6.28	7.37	591.39K
Feb 10, 2026	6.28	6.70	6.20	6.59	271.15K
Feb 09, 2026	6.30	6.60	5.90	6.31	561.27K
Feb 06, 2026	6.22	6.66	6.00	6.26	520.55K
Feb 05, 2026	6.43	6.97	6.02	6.09	607.6K
Feb 04, 2026	6.56	6.70	6.06	6.30	272.9K
Feb 03, 2026	6.33	6.88	6.25	6.55	485.34K
Feb 02, 2026	6.52	6.68	6.22	6.31	297.83K
Jan 30, 2026	6.66	6.80	6.42	6.52	267.7K
Jan 29, 2026	6.95	7.08	6.61	6.63	176.4K
Jan 28, 2026	7.03	7.20	6.91	6.92	304.28K
Jan 27, 2026	6.70	7.14	6.51	7.05	432.84K
Jan 26, 2026	6.58	6.82	6.36	6.65	301.83K
Jan 23, 2026	6.70	7.09	6.54	6.59	323.34K
Jan 22, 2026	6.35	6.64	6.08	6.64	358.07K
Jan 21, 2026	5.96	6.49	5.88	6.32	482.15K
Jan 20, 2026	6.19	6.34	5.89	5.95	423.2K
Jan 16, 2026	6.80	6.85	6.25	6.31	392.74K
Jan 15, 2026	7.17	7.24	6.49	6.66	443.38K

Contact Details

Newton, MA 02459

United States

https://www.karyopharm.com 617 658 0600

About Company

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Stock Peers

ARGX

-1.01-0.12%

argenx SE$833.54 REGN

4.68+0.60%

Regeneron Pharmaceuticals, Inc.$783.65 UTHR

0.28+0.06%

United Therapeutics Corporation$476.13 MDGL

-7.21-1.50%

Madrigal Pharmaceuticals, Inc.$473.79 VRTX

3.78+0.82%

Vertex Pharmaceuticals Incorporated$465.02 PRAX

9.63+2.98%

Praxis Precision Medicines, Inc.$332.92 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-13.8-4.28%

Alnylam Pharmaceuticals, Inc.$308.48 KRYS

-2.39-0.88%

Krystal Biotech, Inc.$270.26 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Frequently Asked Questions

What is the current Karyopharm Therapeutics Inc. (KPTI) stock price?

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) stock price is $8.94 in the last trading session. During the trading session, KPTI stock reached the peak price of $9.94 while $6.72 was the lowest point it dropped to. The percentage change in KPTI stock occurred in the recent session was 21.3% while the dollar amount for the price change in KPTI stock was $1.57.

KPTI's industry and sector of operation?

The NASDAQ listed KPTI is part of Biotechnology industry that operates in the broader Healthcare sector. Karyopharm Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KPTI?

Mr. Michael J. Mano J.D.
Senior Vice President, Gen. Counsel & Sec.
Sarah Connors
Vice President of Corporation Communications
Mr. Ran Frenkel R.Ph., RPh
Global Head of Clinical Operations
Mr. Pierre S. Sayad M.S., Ph.D.
Vice President of Global Medical & Scientific Affairs
Mr. Richard A. Paulson M.B.A.
Pres, Chief Executive Officer & Director
Dr. Sharon Shacham M.B.A., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Mr. Michael P. Mason CPA, M.B.A.
Executive Vice President, Chief Financial Officer & Treasurer
Ms. Sohanya Cheng M.B.A.
Executive Vice President & Chief Commercial Officer
Mr. Stuart Poulton
Executive Vice President & Chief Devel. Officer
Dr. Mansoor Raza Mirza M.D.
Clinical Consultant, Member of Scientific Advisory Board & Independent Director
Mr. Cameron Peters
Vice President of Fin., Assistant Treasurer & Principal Accounting Officer
Ms. Elhan Webb C.F.A.
Senior Vice President of Investor Relations
Mr. James Accumanno J.D.
Chief Compliance Officer

How KPTI did perform over past 52-week?

KPTI's closing price is 154.7% higher than its 52-week low of $3.51 where as its distance from 52-week high of $10.38 is -13.87%.

How many employees does KPTI have?

Number of KPTI employees currently stands at 279.

Link for KPTI official website?

Official Website of KPTI is: https://www.karyopharm.com

How do I contact KPTI?

KPTI could be contacted at phone 617 658 0600 and can also be accessed through its website. KPTI operates from 85 Wells Avenue, Newton, MA 02459, United States.

How many shares of KPTI are traded daily?

KPTI stock volume for the day was 2.75M shares. The average number of KPTI shares traded daily for last 3 months was 311.12K.

What is the market cap of KPTI currently?

The market value of KPTI currently stands at $76.32M with its latest stock price at $8.94 and 8.54M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	279
Beta	0.22
Sales or Revenue	$146.03M
5Y Sales Change%	1.393%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	279
Beta	0.22
Sales or Revenue	$146.03M
5Y Sales Change%	1.393%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

KPTI Company Profile and Key Details

Karyopharm Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook